

# ESRR'24

April 18-21, 2024 – Coimbra, Portugal

21<sup>st</sup> European Symposium on  
Radiopharmacy &  
Radiopharmaceuticals

## FINAL PROGRAMME



We bring ideas to  
life - for a better  
health worldwide.



**ABX advanced biochemical compounds** is a global frontrunner in radiopharmaceuticals, with focus on positron emission tomography (PET) tracers. We develop and produce compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment.

ABX is a global success story: As market leader for radiopharmaceutical consumables we developed over the last years the  $^{177}\text{Lu-PSMA-617}$  – until phase II (then sublicensed to Endocyte, now Novartis) as well as  $^{18}\text{F-PSMA-1007}$  – now approved in several countries in Europe.

## Our expertise



**ABX**



visit our website

# WELCOME ADDRESS

Dear Colleagues and Friends,

It is our pleasure to welcome you to Coimbra to attend the 21<sup>st</sup> European Symposium on Radiopharmacy and Radiopharmaceuticals! Coimbra is a charming city in the center of Portugal. It was the first capital of the country from 1131 and our first kings ruled from here for over a century. The University of Coimbra, founded in 1290, is the oldest Portuguese speaking University and is classified as an UNESCO World Heritage site. Coimbra is embraced by the Mondego River and has lavish gardens, such as the iconic Botanical Garden or the romantic Quinta das Lágrimas, where the immortal love story of Pedro and Inês took place; imposing monuments and churches; fascinating museums and historical places. The congress venue, Convento de São Francisco, was founded in the beginning of the 16th century and throughout its long history served as a convent, a hospital and a military headquarter. It was recently renovated and nowadays it is a pivotal cultural and congress venue for the center of Portugal.

The Institute for Nuclear Sciences Applied to Health (ICNAS) is proud to host the 21<sup>st</sup> European Symposium on Radiopharmacy and Radiopharmaceuticals. ICNAS is a Research Institute of the University of Coimbra, dedicated to Medical Imaging and Translational Research. The Institute is a multimodal and multidisciplinary unit involving more than a hundred collaborators from physics, chemistry, pharmacy, mathematics, engineering, and medicine in an integrative perspective that goes "from molecules to man".

We are confident that the combination of high-level scientific lectures, back-to-basics educational sessions and fruitful discussions, together with nice social events will make the 21<sup>st</sup> edition of ESRR successful, continuing its long-standing tradition of excellence.

Antero Abrunhosa  
Francisco Alves  
Liliana Damas

# TABLE OF CONTENT

<b>1</b>	Welcome Address
<b>4</b>	Organisation
<b>5</b>	Exhibitors & Sponsors
<b>6</b>	Programme Overview
<b>8</b>	Scientific Programme
<b>13</b>	Social Programme
<b>14</b>	Poster Presentations
<b>20</b>	Exhibition Plan







# ORGANISATION

## Scientific Programme Committee:

Chair: Peter Laverman (The Netherlands)  
Martin Behe (Switzerland)  
Filippo Lodi (Italy)  
Jessica Bridoux (Belgium)  
Frederik Cleeren (Belgium)  
Thomas Mindt (Austria)  
Marianne Patt (Germany)

## Local Organising Committee:

Antero Abrunhosa  
Francisco Alves  
Liliana Damas

## Organising Secretariat:

AV ESRR  
c/o EANM Executive Office  
Schmalzhofgasse 26  
1060 Vienna, AUSTRIA  
☎ +43 1 890 44 27  
☎ +43 1 890 44 27-9  
✉ esrr@esrr.info  
🌐 <http://www.esrr.info>

## Congress Venue:

Convento São Francisco  
Avenida da Guarda Inglesa, n.º1A  
3040-193 Santa Clara, Coimbra  
geral@coimbraconvento.pt  
<https://coimbraconvento.pt/pt/>

# EXHIBITORS & SPONSORS

We would like to thank all exhibitors and sponsors of the ESRR 2024 for their support!

 ABX advanced biochemical compounds GmbH	ABX advanced biochemical compounds GmbH
	BIOEMTECH
	Eichrom Technologies
	Elysia-Raytest
	GE HealthCare
	IBA SA
	Ionetix Alpha
	IRE ELIT
	Isotopia Molecular Imaging Ltd.
	ITM Isotopen Technologien München AG
	Jiangsu Huayi Technology Co., Ltd.
	LabLogic Systems Limited
	Molecubes
	Rotem GmbH
	Telix Pharmaceuticals
	Trasis
	Triskem
	Von Gahlen

# PROGRAMME OVERVIEW

Programme information based on March 27, 2024

## Thursday, April 18, 2024

**19:30** Welcome Ceremony & Welcome Lecture: AI in chemistry, with focus on data-driven reaction prediction  
*Teodoro Laino, Zurich*

**20:30** Welcome Reception

## Friday, April 19, 2024

**08:30** Sci Session I – Imaging tracers  
Back-to-basics I: Novel agents and future perspectives on theranostics -  
*Filipe Elvas, Antwerp*

**10:05** Coffee Break

**10:35** Session II – Auger and other therapeutic emitters  
Invited Lecture 1: Auger electron therapy - *Samantha Terry, London*

**12:20** Lunch

**13:45** Session III – New oncological radiotracers  
Invited Lecture 2: Improving radioimmunotherapy with immuno/chemotherapy/  
EBRT – a winning combination? - *Sanne van Lith, Nijmegen*

**15:30** Coffee Break

**16:00** Session IV  
Debate: Small molecules vs peptides vs antibodies vs antibody fragments  
as vector molecule for theranostic radiopharmaceuticals - *Frederik Cleeren,  
Leuven*

**16:45** Poster Pitches (Sala Mondego)

**16:45** Poster viewing + refreshments (Sala Aeminium)

**20:00** Dinner (see page 13)



## Saturday, April 20, 2024

---

08:30	Session V – Radiochemistry Back-to-basics II: Computational methods in radiopharmaceutical sciences - <i>Verena Pichler, Vienna</i>
10:05	Coffee Break
10:35	Session VI – New neurological tracers Invited Lecture 4: Pretargeting strategies, where are we? - <i>Mathias Herth, Copenhagen</i>
12:08	Workshop: EATRIS EU Tracer Factory - <i>Nadja van Camp, The Netherlands</i> <i>Albert D. Windhorst, The Netherlands</i>
13:00	Lunch
14:00	Session VII – New infection and inflammation tracers Invited Lecture 5: Tracking cells with radiopharmaceuticals: strategies and applications - <i>Aljaž Socan, Ljubljana</i>
15:30	Coffee Break
16:00	Session VIII – Round table GMP and Legislation (Annex 1 and 3) Regulators view on Annex 1 for radiopharmaceuticals - <i>Thijs Kroon, Neil Hartman, Oliver Kiss</i>
17:30	Pharmacopoeia Corner - <i>Thijs Kroon, Ellen Pel</i>
20:00	Dinner (see page 13)

## Sunday, April 21, 2024

---

08:30	Session IX – From alpha to beta & back Back-to-basics III: Alpha emitters, from basic physics to labeling and measuring - <i>Janke Kleynhans, Leuven</i>
10:05	Coffee Break
10:35	Session X – Radionuclide production Oral Presentations
11:25	Closing / Awards Ceremony
12:15	Farewell Lunch

# SCIENTIFIC PROGRAMME

Friday, April 19, 2024

---

08:30	Session I – Imaging tracers
10:05	<b>Chairpersons: Jessica Bridoux, Filipe Elvas</b>
08:30	<i>Filipe Elvas:</i> Back-to-basics I: Novel agents and future perspectives on theranostics
09:15	<i>Alexandra Fonseca:</i> OP01 Improved PET imaging of NETs with [61Cu]-NOTA-TATE: a straightforward comparison with [61Cu]-/[68Ga]-DOTA-TATE
09:27	<i>Anna Orlova:</i> OP02 Development of SPECT agent [99mTc]Tc-BQ0413 for PSMA visualization: preclinical evaluation and preliminary results of Phase I clinical study
09:39	<i>Joana Santos:</i> OP03 Folate-targeted polymeric micelles for image-guided drug delivery of an anticancer gold complex
09:51	<i>Emma Nascimbene:</i> OP04 Development and characterization of 99mTc-scFvD2B as a potential theranostic pair for 177Lu-scFvD2B
10:05	Coffee Break
10:35	Session II – Auger and other therapeutic emitters
12:20	<b>Chairpersons: Peter Laverman, Samantha Terry</b>
10:35	<i>Samantha Terry:</i> Invited Lecture 1: Auger electron therapy
11:20	<i>António Paulo:</i> OP05 111In- and 161Tb-Radioconjugates Carrying PSMA and Triphenylphosphonium Derivatives for Auger Therapy of Prostate Cancer
11:32	<i>Marianna Tosato:</i> OP06 Sulfur Symphony: Capturing the Exotic Mercury-197m/g Auger Emitters with Macrocyclic S-Rich Chelators
11:44	<i>Thomas Mindt:</i> OP07 Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97/103
11:56	<i>Aleksander Bilewicz:</i> OP08 Nanobioconjugates of 109Pd/109mAg in-vivo generators for targeted Auger electron therapy

---

12:08	<b>Laurène Wagner:</b> OP09 Synthesis, 68Ga-radiolabelling and in vitro evaluation of a PET/PDT agent for prostate cancer theranostics
12:20	Lunch
13:45	Session III – New oncological radiotracers
15:30	<b>Chairpersons: Sanne van Lith, Inês Farinha Antunes</b>
13:45	<b>Sanne van Lith:</b> Invited Lecture 2: Improving radioimmunotherapy with immuno/chemotherapy/EBRT – a winning combination?
14:30	<b>Sarandeep Kaur:</b> OP10 Structure-based design, optimization and development of [18F]SK60: A Novel PET radioligand for the imaging of mutated Isocitrate Dehydrogenase
14:42	<b>Vladimir Tolmachev:</b> OP11 Molecular Imaging of HER2 Expression in Breast Cancer Using DARPIn [123I]I-(HE)3-G3. From mice to Phase I.
14:54	<b>Herlinde Dierick:</b> OP12 Fully automated production of [18F]FB-labeled single-domain antibodies: the immune-checkpoint TIGIT for PET imaging
15:06	<b>Muriel Aline Spahn:</b> OP13 A novel Al18F-labeled radiotracer for in vivo imaging of CXCR4 using positron emission tomography
15:18	<b>Jonas Schädlich:</b> OP14 Radioiodinated closo-dicarbododecaborane(12)-based cyclooxygenase-2/5-lipoxygenase inhibitors
15:30	Coffee Break
16:00	Session IV
18:00	<b>Chairpersons: Martin Behe, Thomas Mindt</b>
16:00	<b>Frederik Cleeren:</b> Debate: Small molecules vs peptides vs antibodies vs antibody fragments as vector molecule for theranostic radiopharmaceuticals
16:45	Poster Pitches (Sala Mondego)
17:15	Poster & Refreshments (Sala Aeminium)
20:00	Dinner (see page 13)

# SCIENTIFIC PROGRAMME

Saturday, April 20, 2024

---

08:30	Session V – Radiochemistry
10:05	Chairpersons: <b>Matthias Herth, Verena Pichler</b>
08:30	<i>Verena Pichler</i> : Back-to-basics II: Computational methods in radiopharmaceutical sciences
09:15	<i>Magdalena Blei</i> : OP15 Synthesis, stability determination and radiolabeling of new diazabenzene-based azamacrocycles with barium-131, actinium-225, lanthanum-133, and lead-212
09:27	<i>Ludovic Le Saux</i> : OP16 Evaluation of sydnones-based click chemistry for the labeling with heavy radiohalogens
09:39	<i>Eline Hooijman</i> : OP17 From Theory to Clinical Application: Understanding Ac-225 radiochemistry through [225Ac]Ac-DOTA-TATE
09:51	<i>Mátyás Fodor</i> : OP18 Radiolabelling of various macrocyclic ligands using 155Tb/156Tb radioisotopes
10:05	Coffee Break
10:35	Session VI – New neurological tracers
12:20	Chairpersons: <b>Philip Elsinga, Bieneke Janssen</b>
10:35	<i>Mathias Herth</i> : Invited Lecture 4: Pretargeting strategies, where are we?
11:20	<i>Vanessa Tomé</i> : OP19 11C-carboxylations using Grignard reactions for the preparation of [carbonyl 11C]WAY-100635 and [1-11C]Sodium Acetate
11:32	<i>Romy Cools</i> : OP20 Preclinical evaluation of [11C]HSP990 as novel Hsp90 PET brain probe for in vivo visualization of Hsp90 in healthy aging and neurodegeneration
11:44	<i>Johanna Trommer</i> : OP21 Radiolabeling of M13 bacteriophages for in vivo imaging
11:56	<i>Albert D. Windhorst</i> : OP22 Synthesis, in vitro and in vivo evaluation of novel radioligands for $\alpha$ -synuclein PET
12:08	<i>Nadja van Camp, Albert D. Windhorst</i> : Workshop: EATRIS EU Tracer Factory
13:00	Lunch

14:00	Session VII – New infection and inflammation tracers
15:30	<b>Chairpersons: Aljaž Socan, Jan Rijn Zeevaart</b>
14:00	<i>Aljaž Socan</i> : Invited Lecture 5: Tracking cells with radiopharmaceuticals: strategies and applications
14:42	<i>Clemens Decristoforo</i> : OP23 Repurposing a pharmaceutical development for infection theranostics
14:54	<i>Gerbren B. Spoelstra</i> : OP24 Synthesis and preclinical evaluation of novel 18F-vancomycin-based tracers for the detection of bacterial infections using positron emission tomography
15:06	<i>Milos Petrik</i> : OP25 Artificial biomimetic Siderophores as PET radiopharmaceuticals: Radiolabelling and evaluation for PET imaging of invasive aspergillosis
15:18	<i>Julia Greiser</i> : OP26 [68Ga]Ga-TEoS-DAZA as PET tracer for liver function determination and diagnosis of liver-bile-related diseases
15:30	<b>Coffee Break</b>
16:00	Session VIII – Round table GMP and Legislation (Annex 1 and 3)
18:00	<b>Chairpersons: Marianne Patt, Clemens Decristoforo</b>
16:00	Regulators view on Annex 1 for radiopharmaceuticals
16:30	<i>Thijs Kroon</i> : Problems arising from revised Annex 1 for preparation of radiopharmaceuticals
16:50	<i>Neil Hartman</i> : Practical problems with Annex 1 for kit-based Radiopharmaceuticals and how a revision of Annex 3 help with the issues
17:05	<i>Oliver Kiss</i> : Outcome from an ITF EMA meeting of PRISMAP (quality requirements for new radionuclides in clinical trials)
17:15	Discussion
17:30	<i>Thijs Kroon, Ellen Pel</i> : Pharmacopoeia Corner
20:00	Dinner (see page 13)

# SCIENTIFIC PROGRAMME

Sunday, April 21, 2024

---

08:30	Session IX – From alpha to beta and back
10:05	<b>Chairpersons: Janke Kleynhans, Klaus Kopka</b>
08:30	<i>Janke Kleynhans:</i> Back-to-basics III: Alpha emitters, from basic physics to labeling and measuring
09:15	<i>Cristina Müller:</i> OP27 Tumor-targeted alpha therapy using terbium-149 in combination with somatostatin analogues
09:27	<i>Agnieszka Majkowska-Pilip:</i> OP28 Synergistic effects of a combination of trastuzumab-emtansine (T-DM1) and $\beta$ -radiation (198AuNPs) for targeted HER2+ therapy
09:39	<i>Laura De Nardo:</i> OP29 Assessment of cell damage produced by somatostatin analog radiopharmaceuticals labelled with 177Lu or 161Tb
09:51	<i>Zbynek Novy:</i> OP30 Preclinical assessment of enhanced blood retention and tumor uptake PSMA-targeting 225Ac-labeled radioconjugates
10:03	Coffee Break
11:15	Session X – Radionuclide production
11:25	<b>Chairpersons: Nicholas van der Meulen, Tom Christian Adamsen</b>
10:35	<i>Nicholas van der Meulen:</i> IOP31 Terbium-149 production and separation: the latest development update
10:47	<i>Francesca Barbaro:</i> OP32 155Gd-target enrichment for 155Tb production by low-energy cyclotrons
10:59	<i>Giorgia Speltri:</i> OP33 Development of a new technology for the 52Mn-radiopharmaceuticals cyclotron production
11:11	<i>Santiago Brühlmann:</i> OP34 An alternative production route for the PET radionuclide 61Cu: exploring the 62Ni(p,2n)61Cu nuclear reaction
11:25	Closing / Awards Ceremony
12:15	Farewell Lunch



# SOCIAL PROGRAMME



Thursday, April 18, 2024

20:30

Welcome Reception  
(Congress Venue)

Friday, April 19, 2024

19:00

Quinta das Lágrimas,  
Rua António Augusto Gonçalves  
Coimbra, 3041-901

Saturday, April 20, 2024

20:00

Sala D. Afonso Henriques  
(church at congress venue)  
Meeting point in front of the church

Sunday, April 21, 2024

12:15

Farewell Lunch  
(Congress Venue)

# POSTER PRESENTATIONS

**PP01**

**Addressing the side product challenge in copper-mediated radiofluorination**  
Sarandeep Kaur, Germany

**PP02**

**The importance of radiochemical purity: Cellular binding and internalization of different radiometal chlorides in prostate cancer cells**  
Julia Raitanen, Austria

**PP03**

**TECANT Journey: Tracing the Path of  $^{99m}\text{Tc}$ -labelled Somatostatin Antagonist from Concept to Clinical Realization**  
Renata Mikolajczak, Poland

**PP04**

**The potential use of palladium radionuclides for Targeted Auger electron Therapy ( $^{103}\text{Pd}$ ) and theragnostic applications ( $^{109}\text{Pd}$ )**  
Cathryn HS Driver, South Africa

**PP05**

**Fully automated, GMP-compliant, one-pot production of 6-L- $^{18}\text{F}$ FDOPA using an optimized  $^{18}\text{F}$ fluorodestannylation Approach**  
Chantal Kwizera, The Netherlands

**PP06**

**Advancing into the realm of innovative theranostic radionuclides: separation of silver-111 from a neutron-irradiated palladium target**  
Mattia Asti, Italy

**PP07**

**Modelling ligand depletion for simultaneous affinity and binding site quantification on cells and tissue**  
Hadis Westin, Sweden

**PP08**

**Cationic amino acid-based technetium(I)- $^{99m}$  complexes for cancer imaging**  
Rúben Silva, Portugal

**PP09**

**Fast Screening tools: Unveiling molecular insights through nuclear in vivo imaging and efficient preclinical research**  
Sofia Lagoumtzi, Greece

**PP10**

**Preclinical imaging of therapeutic alpha-emitters**  
Sofia Lagoumtzi, Greece

**PP11**

**Microwave in PET Radiochemistry**  
Ângela Neves, Portugal

**PP12**

**Novel concept of a  $^{44}\text{Ti}/^{44}\text{Sc}$  generator**  
Đorđe Cvjetinović, Switzerland

**PP13**

**Automation of  $^{11}\text{C}$ -labelled TSPO-tracer [ $^{11}\text{C}$ ]Me-DPA synthesis with Trasis AllInOne-module**

Edla Kerminen, Finland

**PP14**

**Cytotoxic and Antiproliferative Effects of [ $^{64}\text{Cu}$ ]CuCl<sub>2</sub> in Tumor Cells for Radiometabolic Therapy: a Preliminary Study**

Francesca Porto, Italy

**PP15**

**PSMA-radioligand therapy: Institutional Experience**

Mohammed Al-Qahtani, Saudi Arabia

**PP16**

**Radiolabelling of [ $^{68}\text{Ga}$ ]Ga-NODAGA-Exendin-4 in sodium acetate buffer**

Mailys Ragot, France

**PP17**

**Clearing Agents based on Poly-L-Lysine scaffolds for improved Pretargeted**

**$\alpha$ -Radioimmunotherapy**

Emma Aneheim, Sweden

**PP18**

**Radiolabelled antiangiogenic monoclonal antibody ramucirumab as an effective tool for diagnostics and therapy in nuclear medicine**

Pavel Barta, Czech Republic

**PP19**

**Preparation and evaluation of stabilized  $^{211}\text{At}$ -labelled aryl compounds**

Romain Fouinneteau, France

**PP20**

**Synthesis and characterization of Rhenium and Technetium-99m nitrido complexes with tridentate thiosemicarbazones ligands**

Cristina Bolzati, Italy

**PP21**

**$^{67}\text{Cu}$  produced at a biomedical cyclotron for preclinical in vivo studies**

Ursula Søndergaard, Norway

**PP22**

**Production of research radionuclides for Targeted Auger Electron Therapy (TAET) at TRIUMF**

Valery Radchenko, Canada

**PP23**

**The development of lyophilised kit preparations: Gateway to larger clinical uptake of Ga-68 radiopharmaceuticals**

Jan Rijn Zeevaart, South Africa

# POSTER PRESENTATIONS

**PP24**

**Challenges in IMP preparation for a clinical trial – on the example of DuoNen, personalized PRRT with mixed doses of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE in neuroendocrine neoplasm treatment**

Renata Mikolajczak, Poland

**PP25**

**3D cancer models for the theranostic evaluation of 64CuCl<sub>2</sub>**

Filipa Mendes, Portugal

**PP26**

**The Potential of Terbium-161 labeled Compounds for Clinical Implementation**

Carolline Ntihabose, The Netherlands

**PP27**

**Implementing Ac-225 Labeled Radiopharmaceuticals: Practical Considerations and (Pre-)Clinical Perspectives**

Eline Hooijman, The Netherlands

**PP28**

**Development and primary evaluation of [99mTc]Tc (CO)<sub>3</sub>-NOTA-Erlotinib as a potential radiopharmaceutical for molecular imaging in triple negative breast cancer**

Ana María Rey, Uruguay

**PP29**

**A novel capsule design results in efficient production of 89Zr**

Johan Svedjehed, Sweden

**PP30**

**A novel dual-modality imaging agents targeting FAP based on fusarinine C scaffold**

Giacomo Gariglio, Austria

**PP31**

**Optimization and Automation of Copper-mediated one-step [18F]SFB synthesis starting from the boronic acid pinacol ester**

Markus Laube, Germany

**PP32**

**Implementation of Design of Experiments methodology for optimization of 18F-PSMA-11 radiolabeling with [Al18F]2+ on AIO**

Charlotte Collet-Defossez, France

**PP33**

**Fully-automated production of [18F]Amylovis on the trasis AllinOne module**

Fernando Trejo-Ballado, Mexico

**PP34**

**89Zr-DFO-Atezolizumab for PD-L1 Imaging of Glioblastoma: Clinical Experience**

Anna Kastelik-Hryniewiecka, Poland

**PP35**

**Investigation into the metabolic stability of 18F-labeled PSMA inhibitor derivatives bearing aryl-fluorosulfates for PET tracer development applications**

Guillermo Luque Consuegra, Germany

**PP36****Biodistribution of orally administered nano-particle polymers**

Steen Jakobsen, Denmark

**PP37****Titanium-45 - Production, Extraction and Complexation**

Chubina Kumarananthan, Norway

**PP38****Synthesis and Quality Control of [68Ga]Ga-PSMA-11 Cold Kits Produced Using Two Different Generator Models Simultaneously**

Daniele Alizé, France

**PP39****Improvement of the local macroaggregated albumin (MAA) lyophilised kit**

Putthiporn Charoenphun, Thailand

**PP40****A fast and automated method for the production of [13N]AMMO**

Ole Heine Kvernenes, Norway

**PP41****Exploring the therapeutic efficacy of [177Lu]Lu-DOTA-trastuzumab in trastuzumab-resistant HER2+ lesions**

Liliana Santos, Portugal

**PP42****Sequential labeling of Silk Fibroin Nanoparticles with 99mTc and Indocyanine Green for in vivo SPECT NIR-I/II imaging: Towards photothermal theranostic nanoprobes**

Belén Otero Alonso, Spain

Andrea Blesa Jiménez, Spain

**PP43****211At-labeling of trans-cyclooctenes and cis-cyclooctenes with astatine-211 using electrophilic and nucleophilic reactions**

Maarten Vanermen, Belgium

**PP44****The role of radiopharmaceutical Tc99m MIBI in the evaluation of parathyroid adenoma and osteoporosis in young patients - a case report supporting its integration into standard clinical practice**

Ismet Bajrami, Kosovo

**PP45****In-hospital production and quality control of radiotracer [68Ga]Ga-NODAGA-Exendin-4 on Trasis EasyOne synthesizer**

Sonja Van den Block, Belgium

**PP46****Manufacturing of investigational medicinal products under GMP conditions using the example of a radiopharmaceutical kit PSMA-T4 for technetium-99m labelling**

Anna Drapsa, Poland

# POSTER PRESENTATIONS

**PP47**

**Radionuclidic purity of Ga-68 eluted from Ge-68/Ga-68 generators by Thin Layer Chromatography**

Joao Alberto Osso Junior, Brazil

**PP48**

**[225Ac]Ac-PSMA-D4 as a promising alpha-emitter based radiopharmaceutical Preliminary studies - radiolabelling and quality control**

Marcin Radzik, Poland

**PP49**

**[18F]Fluoromisonidazole synthesis method based on solid-phase extraction (SPE) purification**

Maja Chochevska, North Macedonia

**PP50**

**Pharmacoeconomic analysis as a tool for more objective insight into the idea of introducing new radiopharmaceuticals**

Katerina Kolevska, North Macedonia

**PP51**

**Application of autoradiography to study radionuclide distribution in 3D culture models**

Catarina Pinto, Portugal

**PP52**

**Validation of an in-house process for the production of Sodium [18F]fluoride radiopharmaceutical**

Marija Atanasova Lazareva, North Macedonia

**PP53**

**Preliminary evaluation of a novel Temozolomide-based molecule radiolabeled with 99mTc as a theranostic agent against glioblastoma**

Penelope Bouziotis, Greece

**PP54**

**PSMA-targeted Radioconjugates Bearing a DNA Intercalator for Enhanced Auger Therapy of Prostate cancer**

Catarina Dorisa Silva, Portugal

**PP55**

**Therapeutic Efficacy of 177Lu-DMSA-SPIONs in a Mouse CT26 and 4T1 Xenograft Model**

Dragana Stanković, Serbia

**PP56**

**NOAR - Network for Optimized Astatine-211 labeled Radiopharmaceuticals EU COST Action CA19114**

Dana Niculae, Romania



**PP57**

**Automated production of [68Ga]Ga-deferoxamine on two different synthesis modules for bacterial infection imaging**

Martin Kraihammer, Austria

**PP58**

**First automatic multidose injection of the <sup>177</sup>Lu-ITG-PSMA-1 in Bosnia and Herzegovina**

Aljoša Stanković, Bosnia & Herzegovina

**PP59**

**Unlocking the potential of <sup>45</sup>Ti for PET-imaging: the formation and evaluation of the Ti-DOTA complex**

Eduard Pogorilyy, Norway

**PP60**

**Automated fluorine-18 radiolabelling via alkyne-azide cycloaddition reaction on dual peptide-functionalized liposomes surface for in vivo PET imaging**

Marco Nicola Iannone, Italy

**PP61**

**Development of [<sup>18</sup>F]AlF-RESCA-FSH as a diagnostic probe for ovarian cancer.**

Maria Kominia, The Netherlands

**PP62**

**Design and evaluation of Cu(II)-HMPAO complex as a representative model for assessing the potential of <sup>64</sup>Cu radiopharmaceutical**

Marija Mirković, Serbia

**PP63**

**Using Epin boronic esters as substrates improves the copper-mediated [<sup>18</sup>F]-fluorination of arenes**

Annemarie Doze, The Netherlands

**PP64**

**Effects of the conjugation method on the stability of a <sup>161</sup>Tb-labeled antibody**

Camille Van Laere, Belgium

**PP65**

**Liquid target production of zirconium-89 for antibody labelling**

Agnieszka Chmura, Poland

**PP66**

**Copper-61: From Bench to Bedside**

Nicole Schubert, Austria

# EXHIBITION PLAN

## Venue Overview

The scientific programme will be held in **Sala Mondego** which is located on the second floor.  
The industry exhibition will be set up in **Sala Aeminium** which is on the first floor.

## Main Entrance


Convento São Francisco  
Avenida da Guarda Inglesa, n.º1A  
3040-193 Santa Clara, Coimbra

## Industry Exhibition

Floor 1 - Sala Aeminium

## Scientific Programme

Floor 2 - Sala Mondego



## Booth Company

---

<b>01</b>	IRE ELiT
<b>02</b>	Von Gahlen
<b>03</b>	Elysia-Raytest
<b>04</b>	Rotem GmbH
<b>05</b>	Telix Pharmaceuticals
<b>06</b>	Ionetix Alpha
<b>07</b>	Molecubes
<b>08</b>	ABX advanced biochemical compounds GmbH
<b>09</b>	Triskem
<b>10</b>	LabLogic Systems Limited
<b>11</b>	IBA SA
<b>12</b>	Eichrom Technologies
<b>13</b>	Isotopia Molecular Imaging Ltd.
<b>14</b>	Trasis
<b>15</b>	Jiangsu Huayi Technology Co., Ltd.
<b>16</b>	BIOEMTECH
<b>17</b>	ITM Isotopen Technologien München AG
<b>18</b>	GE HealthCare

## Highly selective resins for radiometal purification

Separation methods for Ga-68, Cu-61/4/7, radiolanthanides (Lu-177, Tb-161,...), Zr-89, Ge-68, alpha emitters (Ac-225, Pb-212,...), Ti-44/5 and many more.

Rapid, highly specific separation techniques  
Separation of radionuclides from irradiated targets  
Quality control of radionuclides for medical use  
R&D and method development  
Radioprotection and Radioanalysis

## Meet us at our booth n° 9

To keep up to date with our new developments  
subscribe to our newsletter.











# CMO Services for Radiopharmaceuticals

## APIs

We have the flexibility to run multiple chemical processes simultaneously to support late development phase to commercial products. State-of-the-art QC laboratories integrated across a highly experienced team focused on commercial readiness and manufacturing expertise.

Full support for method development, validation, and transfer services, as well as submission, audit and manufacturing support.

- PSMA 11
- chrial-PSMA I&T



Scan for more compounds

## Cassettes

With years of experience, we offer GMP-compliant cassette production services for your new radiolabeled compounds, supporting your innovative radiopharmaceutical development.

## Ready-to-use kits for $^{18}\text{F}$ -FDOPA production

IBA Synthera+ synthesis module



Scan for more RTU kits



Reagents Kit | RK-209



Precursor | BBTE-95-0020E



Ancillaries Set | AS-209



Cassette | SYFR

### International

+1 416 298 3366  
Antony@huayi-isotopes.com

### China

+86 512 52451806  
sales@huayitec.net

www.huayitec.net

Follow us:   